Related Experiment Video
Updated: Jun 5, 2025

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
Published on: June 26, 2020
A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide
Nan Sun1, Qun Chen2, Hao Chen3,1
1Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Background:
Temozolomide (TMZ) is used in the treatment of glioblastoma (GBM). However, the primary obstacle remains the emergence of TMZ chemotherapy resistance. Non-POU domain-containing octamer-binding protein (NONO) and splicing factor proline/glutamine rich (SFPQ) are multifunctional nuclear proteins involved in genome stability and gene regulation. However, the specific role of NONO and SFPQ in TMZ resistance of GBM remains to be explored.
Methods:
RNA-binding protein immunoprecipitation-microarray and RNA microarray of TMZ-resistant and parental cells were performed for the gain of HSD52. The effects of HSD52 on TMZ resistance were investigated through in vitro assays, intracranial xenograft, and GBM organoid models. The underlying mechanisms were explored by DNA methylation chip, RNA immunoprecipitation, RNA pull-down assays, among others. GBM clinical samples were rolled in to investigate the clinical significance of HSD52.
Results:
We identified a novel noncoding RNA, HSD52, that was highly expressed in TMZ-resistant GBM and facilitated the interaction between NONO and SFPQ. H3 ubiquitination attenuation and reduced DNA methyltransferase 1 (DNMT1) recruitment increased HSD52 transcription via DNA hypo-methylation. HSD52 formed an RNA duplex with UFM1 specific ligase 1 (UFL1) mRNA, thereby promoting NONO/SFPQ complex binding to UFL1 mRNA and enhancing its stability, and then contributed to TMZ resistance through activating the ataxia telangiectasia mutated signaling pathway. In vivo xenograft and GBM organoid models showed significant repression in tumor growth after HSD52 knockout with TMZ treatment. In GBM clinical samples, HSD52 was responsible for the malignant progression and TMZ resistance.
Conclusions:
Our results revealed that HSD52 could serve as a promising therapeutic target to overcome TMZ resistance, improving the clinical efficacy of TMZ chemotherapy in GBM.
Insights
A novel noncoding RNA, HSD52, drives temozolomide (TMZ) resistance in glioblastoma (GBM) by stabilizing NONO/SFPQ interactions. Targeting HSD52 offers a promising strategy to enhance TMZ chemotherapy efficacy in GBM patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma (GBM) treatment faces a major hurdle due to emerging temozolomide (TMZ) resistance.
- Non-POU domain-containing octamer-binding protein (NONO) and splicing factor proline/glutamine rich (SFPQ) are key nuclear proteins involved in genome stability and gene regulation.
- The specific role of NONO and SFPQ in GBM's TMZ resistance remains largely unexplored.
Purpose of the Study:
- To investigate the role of NONO and SFPQ in TMZ resistance in glioblastoma.
- To identify novel molecular targets for overcoming TMZ resistance in GBM.
- To explore the therapeutic potential of targeting identified mechanisms to improve GBM treatment outcomes.
Main Methods:
- RNA-binding protein immunoprecipitation-microarray and RNA microarray were utilized to identify HSD52 in TMZ-resistant and parental GBM cells.
- In vitro assays, intracranial xenograft, and GBM organoid models were employed to assess HSD52's impact on TMZ resistance.
- Mechanisms were elucidated using DNA methylation chip, RNA immunoprecipitation, and RNA pull-down assays, with analysis of GBM clinical samples.
Main Results:
- A novel noncoding RNA, HSD52, was identified and found to be highly expressed in TMZ-resistant GBM, facilitating NONO and SFPQ interaction.
- HSD52 transcription is upregulated via DNA hypomethylation through H3 ubiquitination attenuation and reduced DNMT1 recruitment.
- HSD52 promotes NONO/SFPQ complex binding to UFL1 mRNA, enhancing its stability and activating the ATM signaling pathway, ultimately conferring TMZ resistance.
Conclusions:
- HSD52 plays a critical role in promoting malignant progression and TMZ resistance in glioblastoma.
- HSD52 facilitates TMZ resistance by stabilizing the NONO/SFPQ complex and activating the ATM signaling pathway.
- HSD52 represents a promising therapeutic target for overcoming TMZ resistance and improving the clinical efficacy of TMZ chemotherapy in GBM.
More Related Videos
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Homologous Recombination
DNA Damage Can Stall the Cell Cycle
Base-pairing and DNA Repair

